Intra-Cellular Therapies Q3 GAAP EPS $(0.25) Vs $(0.57) Last Year, Sales $126.17M Beat $119.23M Estimate
Portfolio Pulse from Benzinga Newsdesk
Intra-Cellular Therapies reported Q3 GAAP EPS of $(0.25), a 56.14% increase over last year's $(0.57). The company's quarterly sales were $126.17M, beating the analyst consensus estimate of $119.23M by 5.82% and marking a 75.56% increase over last year's $71.87M.
November 02, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Intra-Cellular Therapies reported improved Q3 earnings and sales, beating analyst estimates. This could positively impact the company's stock.
Intra-Cellular Therapies reported a significant improvement in its Q3 earnings and sales, beating analyst estimates. This positive financial performance could increase investor confidence and drive the company's stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100